Global Pruritus Therapeutics Market Poised for Growth, Expected to Reach $14.99 Billion by 2028

The Business Research Company's Pruritus Therapeutics Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LANDON, GREATER LANDON, UK, June 28, 2024 /EINPresswire.com/ -- The global pruritus therapeutics market has grown strongly in recent years. It is projected to grow from $11.39 billion in 2023 to $12.03 billion in 2024, at a CAGR of 5.6%. Despite various challenges, the market is anticipated to reach $14.99 billion by 2028, driven by expanding knowledge of pruritus pathophysiology, innovative drug formulations, and a focus on personalized medicine.

Rise in Dermatological Disorders Drives Market Growth
The rise in the incidence of dermatological disorders is expected to propel the growth of the pruritus therapeutics market. Dermatological disorders refer to skin, hair, nail, and mucous membrane disorders, ranging from acne and eczema to skin cancer and fungal infections. For instance, according to a report published by the American Cancer Society Inc. in January 2022, the estimated cases of skin cancer increased to 106,110 in 2021, a rise of 5.8% from 100,350 in 2020. Therefore, the increase in dermatological disorders is driving the growth of the pruritus therapeutics market.

Explore comprehensive insights into the global pruritus therapeutics market with a detailed sample report: https://www.thebusinessresearchcompany.com/sample_request?id=11907&type=smp

Major Players and Market Trends
Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Bausch Health Companies Inc., and Brunswick Corporation.

These companies are focusing on developing innovative treatments such as oral solutions for the management of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. For example, in September 2021, Mirum Pharmaceuticals, Inc. received FDA approval for LIVMARLI (maralixibat) oral solution for managing cholestatic pruritus in individuals aged one year and older with ALGS. This approval highlights the market's emphasis on innovative solutions and personalized therapeutic approaches.

Segments:
• Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products
• Route of Administration: Oral, Parenteral, Topical
• Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
• End-User: Hospitals, Clinics, Other End Users

Geographical Insights: North America Leading the Market
North America was the largest region in the pruritus treatment market in 2023, while Asia-Pacific is expected to be the fastest-growing region during the forecast period. The report provides detailed insights into regional dynamics, market trends, and growth opportunities across various regions.

Order your report now for swift delivery https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Pruritus Therapeutics Global Market Report 2024 from TBRC covers the following information:
• Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.
The Pruritus Therapeutics Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on pruritus therapeutics market size, pruritus therapeutics market drivers and trends, pruritus therapeutics market major players, competitors' revenues, market positioning, and market growth across geographies. The pruritus therapeutics market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
Blood Cancer Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Biologics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Rituximab Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

About The Business Research Company
The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
X
LinkedIn